A Comprehensive Analysis of Goeddel's Innovative Work in Biotechnology
United States Patent 7,754,858 B2 represents a significant advancement in the field of biotechnology, credited to scientist Goeddel and colleagues. This patent addresses critical challenges in molecular biology and has paved the way for numerous applications in medicine and industry.
| Patent Number: | US 7,754,858 B2 |
| Title: | Methods and Compositions for Protein Production |
| Inventor: | Goeddel, David V. |
| Assignee: | Genentech, Inc. |
| Priority Date: | March 15, 2006 |
| Issue Date: | July 13, 2010 |
This patent falls within the field of molecular biology and biotechnology, specifically relating to improved methods for producing recombinant proteins in host cells.
The late 20th century witnessed remarkable advances in recombinant DNA technology, enabling the production of therapeutic proteins in heterologous host systems. However, significant challenges remained in achieving high yields of properly folded, biologically active proteins 1 .
Early recombinant DNA techniques developed, allowing gene cloning in bacteria 2 .
First recombinant protein drug (human insulin) approved for medical use 3 .
Increasing complexity of therapeutic proteins highlighted limitations in expression systems 4 .
Need for improved yield and efficiency in protein production drives new innovation 5 .
Low expression levels, improper protein folding, and host cell toxicity limited production efficiency.
Growing market for biologic drugs required scalable, cost-effective manufacturing processes.
US Patent 7,754,858 B2 discloses novel compositions and methods that significantly improve recombinant protein production. The invention addresses key bottlenecks in existing expression systems through innovative vector design and host cell engineering.
The patented technology demonstrates a 3-5 fold increase in protein yield compared to conventional methods, with maintained biological activity and reduced production of misfolded variants.
The technology described in US 7,754,858 B2 has broad applications across multiple sectors of biotechnology and medicine. Its impact extends from basic research to commercial production of therapeutic proteins.
Production of monoclonal antibodies, hormones, cytokines, and other biologic drugs with improved efficiency.
Enhanced production of enzymes and other proteins for laboratory research and diagnostic applications.
Cost-effective manufacturing of enzymes for food processing, biofuel production, and other industrial applications.
Reduction in manufacturing costs
Faster production timeline
Increase in production scale
Purity of final product
Since its issuance, US Patent 7,754,858 B2 has had a substantial impact on both scientific research and commercial biotechnology. The technology has been implemented in numerous production processes and has contributed to the development of several approved therapeutics.
"The advancements described in this patent represent a significant step forward in our ability to produce complex therapeutic proteins efficiently and at commercial scale. This technology has become foundational to modern biomanufacturing."
References will be populated here based on further research into the specific patent details and related scientific literature.